Nebivolol/valsartan combination for the treatment of hypertension: a review

Nebivolol (N) is a β -adrenoreceptor antagonist that is approved for treatment of hypertension in the USA. Effective treatment of hypertension is becoming an increasingly difficult process that often requires multiple drug combinations to meet target guidelines. This has resulted in the increasing i...

Full description

Saved in:
Bibliographic Details
Published in:Future cardiology 2021-07, Vol.17 (4), p.573-583
Main Authors: Wang, Sarah J, Sander, Gary E
Format: Article
Language:English
Subjects:
aldosterone
angiotensin II receptor blockers
hypertension
mechanism of action
nebivolol
renin-angiotensin system inhibitors
valsartan
vasodilation
β-blockers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nebivolol (N) is a β -adrenoreceptor antagonist that is approved for treatment of hypertension in the USA. Effective treatment of hypertension is becoming an increasingly difficult process that often requires multiple drug combinations to meet target guidelines. This has resulted in the increasing introduction of multidrug single-pill combinations (SPCs) to facilitate cost and compliance issues. Some of the SPCs have added valsartan (V), an angiotensin receptor blocker, which is an increasingly advocated antihypertensive class. Pharmacological profiles of N and V, alone and combined, are well characterized. In 2007, the SPC of N and V, 5 and 80 mg, respectively, was approved by the US FDA for treatment of hypertension. This paper will summarize and update key issues in pharmacology, clinical use and benefit.
ISSN:1479-6678
1744-8298
DOI:10.2217/fca-2020-0079